drugset
drugset / Trial / NCT04908722

A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

NCT04908722 ↗

Phase 3 Completed 1609 enrolled Janssen Vaccines & Prevention B.V.
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to demonstrate non-inferiority (NI) in terms of humoral immune responses after 6 dose levels of Ad26.COV2.S.

Timeline

Start
2021-06-18
Primary completion
2023-07-10
Completion
2023-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad26.COV2.S Vaccine — Intramuscular

Indications

No indication recorded.